UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington D. C. 20549

                                   FORM 10-QSB

                   QUARTERLY REPORT UNDER SECTION 13 OR 15 (D)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                  For the quarterly period ended March 31, 2004

                        Commission file number 333-63432

                                 ORGANETIX, INC.
--------------------------------------------------------------------------------
        (Exact name of small business issuer as specified in its charter)

           Delaware                                           73-1556428

(State or other jurisdiction of                            (I.R.S. Employer
 incorporation or organization)                           Identification No.)

             603 - 7th Avenue S.W., Calgary, Alberta, Canada T2P 2T5
               (Address of principal executive offices) (Zip Code)

                    Issuer's telephone number: (403) 261-8888
                    (Address of principal executive offices)

              (Former name, former address and former fiscal year,
                         if changed since last report.)

Check  whether  the issuer  (1) has filed all  reports  required  to be filed by
Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or for such
shorter period that the  registrant was required to file such reports),  and (2)
has been subject to such filing  requirements  for the past 90 days.
Yes [X] No [ ]

State the number of shares outstanding of each of the issuer's classes
of common equity, as of the latest practicable date.

The number of shares of the issuer's outstanding common stock, which is the only
class of its common equity, on April 26, 2004 was 78,217,456.


<PAGE>

                                 ORGANETIX, INC.
                          (A DEVELOPMENT STAGE COMPANY)

                                      INDEX
<Table>
<Caption>
        PART I          FINANCIAL INFORMATION                                                                      PAGE(S)

        Item 1.         Financial Statements:
        <S>           <C>                                                                                           <C>

                        Balance Sheets - March 31, 2004 (unaudited) and December 31, 2003                             3.

                        Statements of Operations -Three Months Ended March 31, 2004 and the Period from
                        Inception (May 28, 2003) to March 31, 2004                                                    4.

                        Statements of Cash Flows - Three Months Ended March 31, 2004 and the Period from
                        Inception (May 28, 2003) to March 31, 2004                                                    5.

                        Notes to Interim Financial Statements (unaudited)                                             6.

        Item 2.         Management's Discussion and Analysis of Financial Condition and Results of Operations         8.

        Item 3.         Controls and Procedures                                                                      10.


        PART II         OTHER INFORMATION

                        Signatures

                        Exhibits
</Table>


<PAGE>


PART 1 - FINANCIAL INFORMATION

ITEM 1 - FINANCIAL STATEMENTS

                                 ORGANETIX, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                                  BALANCE SHEETS

<Table>
<Caption>
                                                                           March 31,           December 31,
                                                                             2004                 2003
                                                                      -----------------     -----------------
                                                                         (UNAUDITED)
                                   - ASSETS -
<S>                                                                   <C>                   <C>
CURRENT ASSETS:
     Cash                                                              $         141,167     $         186,235
     Raw material inventory                                                       77,000                15,000
     Prepaid expenses                                                              5,000                10,000
                                                                       -----------------     -----------------
TOTAL CURRENT ASSETS                                                             223,167               211,235

OTHER ASSETS:
     License agreement - net of accumulated amortization                       2,132,563             2,146,250
                                                                       -----------------     -----------------

                                                                       $       2,355,730     $       2,357,485
                                                                       =================     =================
                    - LIABILITIES AND SHAREHOLDERS' EQUITY -

CURRENT LIABILITIES:
     Accounts payable and accrued expenses                             $           4,383     $          11,490
     Due to affiliate                                                             64,966                52,656
     Due to shareholders                                                          58,669               122,261
                                                                       -----------------     -----------------
TOTAL CURRENT LIABILITIES                                                        128,018               186,407
                                                                       -----------------     -----------------
COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' EQUITY:
 Common  stock,  $.0001  par  value;  100,000,000  shares
    authorized; 81,234,857 and 76,362,056 shares issued and                       8,123                 7,636
    outstanding in 2004 and 2003, respectively                                2,786,934             2,564,364
 Additional paid-in capital, Subscription receivable                             (4,800)               (6,240)
 Deficit accumulated during the development stage                              (562,545)             (394,682)
                                                                      ------------------    ------------------
                                                                              2,227,712             2,171,078
                                                                      ------------------    ------------------

                                                                      $       2,355,730     $       2,357,485
                                                                       =================     =================
</Table>


                            See accompanying notes.
                                                                        Page 3.


<PAGE>

                                 ORGANETIX, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                            STATEMENTS OF OPERATIONS
                                   (UNAUDITED)

<Table>
<Caption>
                                                                    For the Period From
                                                                     Inception (May 28,
                                                                     2003) to March 31,   Three Months Ended
                                                                           2004             March 31, 2004
                                                                      ---------------       ---------------
<S>                                                                  <C>                   <C>
REVENUES                                                              $            -        $            -
                                                                      ---------------       ---------------

COSTS AND EXPENSES:
     Operating expenses - research facility                                    60,260                17,000
     Research and development expenses                                        155,801                36,575
     Consulting fees                                                           99,528                35,000
     Professional fees                                                         78,206                17,765
     Travel and accommodations                                                 36,096                13,279
     Telephone                                                                 12,558                 2,751
     Insurance                                                                  4,603                    -
     Rent                                                                       8,713                 3,175
     Shipping expense                                                           1,863                   143
     Office and other expense                                                  27,080                 8,088
     Marketing and public relations                                            20,400                20,400
     Amortization expense                                                      57,437                13,687
                                                                      ---------------       ---------------
                                                                              562,545               167,863
                                                                      ---------------       ---------------

NET LOSS                                                              $      (562,545)      $      (167,863)
                                                                      ================      ===============
LOSS PER SHARE:
     Basic and diluted                                                $         (.01)       $            -
                                                                      ================      ===============
     Weighted average number of common shares outstanding                  55,324,497            77,279,561
                                                                      ===============       ===============
</Table>

                             See accompanying notes.

                                                                        Page 4.
<PAGE>


                                 ORGANETIX, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                            STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)

<Table>
<Caption>
                                                                        For the Period
                                                                        From Inception
                                                                       (May 28, 2003) to   Three Months Ended
                                                                        March 31, 2004       March 31, 2004
                                                                      ---------------      ----------------
      <S>                                                               <C>                     <C>
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS:

CASH FLOWS FROM OPERATING ACTIVITIES:
         Net loss                                                          $ (562,545)          $ (167,863)
   Adjustment  to  reconcile  net  loss to net  cash  utilized
        by  operating activities: Amortization                                 57,437               13,687
   Changes in assets and liabilities:
     Raw material inventory                                                   (77,000)             (62,000)
     Prepaid expenses                                                          (5,000)               5,000
     Accounts payable and accrued expenses                                      4,383               (7,107)
     Due to affiliates                                                         64,966               12,310
     Due to shareholders                                                       58,669              (63,592)
                                                                      ---------------      ----------------
        NET CASH UTILIZED BY OPERATING ACTIVITIES                            (459,090)            (269,565)
                                                                      ----------------     ----------------

CASH FLOWS FROM INVESTING ACTIVITIES
     Payment regarding license                                               (150,000)                    -
                                                                      ----------------       --------------
        NET CASH UTILIZED BY INVESTING ACTIVITIES                            (150,000)                    -
                                                                      ----------------       --------------

CASH FLOWS FROM FINANCING ACTIVITIES:
     Issuance of common stock to founders                                      65,760                    -
     Proceeds from private placement of common stock                          384,497              224,497
     Cash received in merger                                                  300,000                    -
                                                                      ---------------      --------------
        NET CASH PROVIDED BY FINANCING ACTIVITIES                             750,257              224,497
                                                                      ---------------      ---------------
        NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS                  141,167              (45,068)
                                      Cash, beginning of period                    -               186,235
                                                                      ---------------      ---------------
                                     CASH, END OF PERIOD              $       141,167      $       141,167
                                                                      ===============      ===============
</Table>

                             See accompanying notes.

                                                                         Page 5.
<PAGE>


                                 ORGANETIX, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                 NOTES TO UNAUDITED INTERIM FINANCIAL STATEMENTS
                                 MARCH 31, 2004

NOTE 1 -      DESCRIPTION OF COMPANY/OPERATIONS:

              Organetix,  Inc.  ("the  Company"  or  "Organetix"),   a  Delaware
              Corporation, was incorporated on May 28, 2003.

              The  Company is a  biotechnology  company  that has the  exclusive
              worldwide  license  (see Note 3) for the formula of a  proprietary
              medical  discovery  relating  to the liver.  Organetix  intends to
              patent, research, develop, produce and sell this proprietary liver
              product initially as a nutra-ceutical/herbal  supplement, referred
              to  as  "A4+L   Compound".   This  liver  product  has  been  used
              specifically to treat patients with Hepatitis C. Organetix intends
              to  also  specialize  in  researching,  developing  and  patenting
              bioactive  compounds and their unique  formulas and processes from
              plants having a distinctive history of medicinal use.

              On November 7, 2003 (the  "Effective  Date"),  pursuant to a Share
              Exchange  Agreement  ("Agreement")  between Diamond  International
              Group,  Inc.  ("Diamond"),  a Delaware  corporation and Organetix,
              Inc.  ("Organetix"),   a  Delaware  corporation  and  all  of  the
              shareholders of Organetix,  Diamond  acquired all of the shares of
              Organetix  as   consideration   for  the  issuance  of  64,000,000
              restricted shares of Diamond to the Organetix  shareholders.  As a
              result of this Agreement,  Diamond  International Group, Inc. (the
              legal acquirer) received 100% of the issued and outstanding common
              stock of  Organetix,  Inc. in exchange  for  64,000,000  shares of
              common  stock of  Diamond.  Pursuant to the  Agreement,  Organetix
              became a wholly owned  subsidiary  of Diamond which entity filed a
              Certificate of Amendment  with the State of Delaware  changing its
              name to  Organetix,  Inc.  This  reverse  merger  transaction  was
              treated retroactively as a recapitalization  with Organetix,  Inc.
              being treated as the accounting acquirer.

              The Company has been  devoting its time towards  establishing  its
              business and no revenues have been generated to date. As such, the
              Company is considered as being in the development stage, since its
              inception,  in accordance  with Statement of Financial  Accounting
              Standards No. 7, and its year-end is December 31.

              In the opinion of management,  the accompanying  unaudited interim
              consolidated   financial  statements  of  Organetix,   Inc.  ("the
              Company"), contain all adjustments (consisting of normal recurring
              accruals and adjustments)  considered  necessary to present fairly
              the  Company's  financial  position  as of March 31,  2004 and the
              results of its  operations and its cash flows for the three months
              ended March 31, 2004 and the period from  inception (May 28, 2003)
              to March 31,  2004.  Operating  results for the three months ended
              March 31, 2004 are not necessarily  indicative of the results that
              may be expected for the year ended December 31, 2004.

              The accounting  policies  followed by the Company are set forth in
              Note 2 to  the  Company's  financial  statements  included  in its
              annual report on Form 10-KSB for the year ended December 31, 2003,
              which is incorporated  herein by reference.  Specific reference is
              made to this report for a description of the Company's  securities
              and the  notes  to  financial  statements  included  therein.  The
              accompanying unaudited interim condensed financial statements have
              been prepared in accordance with accounting  principles  generally
              accepted in the United  States of America  for  interim  financial
              information and with the instructions to Form 10-QSB. Accordingly,
              they do not include all of the information and footnotes  required
              by accounting  principles  generally accepted in the United States
              of America.

NOTE 2 -      DUE TO AFFILIATE/SHAREHOLDERS:

              The  Company is  indebted  to certain of its  shareholders  and an
              affiliate,  Amma  Corporation,  for expenses  (administrative  and
              managerial  costs)  incurred  in  connection  with  the  Company's
              operations from inception.  These amounts are non-interest bearing
              and are payable on demand.


                                                                        Page 6.
<PAGE>


                                 ORGANETIX, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                 NOTES TO UNAUDITED INTERIM FINANCIAL STATEMENTS
                                 MARCH 31, 2004

NOTE 3 - ASSIGNMENT OF LICENSE AND CONSULTING AGREEMENTS:

   (A) LICENSE AGREEMENT:

       On July 15, 2003,  Amma  Corporation  ("Amma"),  a privately  held entity
       domiciled in Alberta, Canada, assigned, to the Company, all of its right,
       title and  interest  in and to the A4+L  compound as defined in a License
       Agreement,  dated  June 5, 2003,  between  Amma and Dr.  Jose  Cabanillas
       Coral, a Canadian resident and citizen of Peru, in exchange for 8,160,000
       shares of Company common stock.

       The A4+L compound (the  "technology"),  is a multiple  plant  formulation
       used for the relief of certain medical symptoms associated with Hepatitis
       C.  This  license  grants  the  Company  the  exclusive  right to use and
       sublicense  the  technology,  and  any  improvements,  and  to  research,
       manufacture,  distribute and sell products throughout the world excluding
       Peru.  This 40-year  license also requires that the Company pay a royalty
       equal to 3% of gross sales and sublicensing revenues to Dr. Cabanillas.

   (B) CONSULTING AGREEMENT:

       Concurrently  with the  assignment  of the  license  agreement  described
       above, Amma also assigned its consulting  agreement,  dated June 1, 2001,
       with Dr. Cabanillas to the Company. This agreement, which expires on June
       1, 2006, requires that Dr. Cabanillas provide general and research duties
       as requested, in exchange for a monthly fee of $12,000.


NOTE 4 - STOCKHOLDERS' EQUITY:

       The Company has authorized 100 million shares of common stock,  par value
       $.0001 per share.

       During the quarter ended March 31, 2004, the Company received $125,000 in
       exchange  for the  issuance  of  1,000,000  shares of common  stock.  The
       Company also issued  855,400  common shares for aggregate net proceeds of
       $98,057. The Company declared a 10% stock dividend and accordingly issued
       3,017,401 shares of common stock.

                                                                        Page 7.

<PAGE>


       ITEM 2. - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
       RESULTS OF OPERATIONS

       CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS

       It should be noted that this  Management's  Discussion  and  Analysis  of
       Financial    Condition   and   Results   of   Operations    may   contain
       "forward-looking   statements."   The  terms   "believe,"   "anticipate,"
       "intend,"  "goal,"   "expect,"  and  similar   expressions  may  identify
       forward-looking  statements.  These forward-looking  statements represent
       the Company's current  expectations or beliefs  concerning future events.
       The matters covered by these  statements are subject to certain risks and
       uncertainties  that could cause actual results to differ  materially from
       those  set  forth  in  the  forward-looking  statements,   including  the
       Company's  dependence  on  weather-related   factors,   introduction  and
       customer acceptance of new products,  the impact of competition and price
       erosion,  as well as supply and manufacturing  restraints and other risks
       and  uncertainties.  The  foregoing  list  should  not  be  construed  as
       exhaustive,  and the Company  disclaims any  obligation  subsequently  to
       revise any forward-looking  statements to reflect events or circumstances
       after  the date of such  statements,  or to  reflect  the  occurrence  of
       anticipated  or  unanticipated   events.  In  light  of  the  significant
       uncertainties  inherent  in  the  forward-looking   information  included
       herein,  the  inclusion of such  information  should not be regarded as a
       representation  that  the  strategy,  objectives  or  other  plans of the
       Company will be achieved.  The Company  wishes to caution  readers not to
       place undue reliance on any such forward-looking statements,  which speak
       only as of the date made.

       OVERVIEW

       Organetix is a  biotechnology  company that has the  exclusive  worldwide
       license for the formula of a proprietary  medical  discovery  relating to
       the liver.  Organetix will patent,  research,  develop,  produce and sell
       this proprietary liver product  initially as a nutraceutical.  This liver
       product has been used  specifically  to treat  patients with Hepatitis C.
       Limited  research  shows that the product  regenerates  liver tissue thus
       allowing the liver to begin  functioning  again  despite  years of damage
       from the virus.  Therefore,  this  product may be useful for treating all
       liver disorders  including cirrhosis and may someday eliminate most liver
       transplants.  Much like insulin being used for diabetes, this proprietary
       liver  product  does  not  cure  Hepatitis  C but has the  capability  of
       regenerating the liver.

       Management,  together  with  research and medical  advisors are reporting
       that the formula, in the limited tests conducted to date, eliminates most
       of the symptoms of Hepatitis C quickly and effectively  without any known
       side effects. The liver product will directly compete in a billion dollar
       market that currently exists around the world. Additional testing will be
       ongoing. Analog products will also be evaluated.

       Organetix  will  specialize  in  researching,  developing  and  patenting
       bioactive  compounds and their unique  formulas and processes from plants
       having a unique history of medicinal use. We feel that Nutraceuticals and
       Bioceuticals  are the  foundations  for the new and exciting  drugs to be
       discovered in the 21st Century.

       The following describes the Company's immediate priorities:

      o Register patents and research  synthesis of the existing  nutraceuticals
        and bioceuticals from the licensed liver product;

      o Complete a larger clinical study of Hepatitis C patients  suffering from
        severe symptoms and late stages of liver disease;

      o Sub-license,  market and  distribute  the licensed  liver products with
        strategic partners;


                                                                        Page 8.
<PAGE>

      o Develop new  nutraceuticals  and  bioceuticals  from the licensed  liver
        product.

      The following should be read in conjunction with our financial  statements
      and the related  notes that appear  elsewhere in this Annual  Report.  The
      discussion  contains  forward-looking  statements  that reflect our plans,
      estimates and beliefs.  Our actual  results could differ  materially  from
      those  discussed  in the  forward-looking  statements.  Factors that could
      cause or contribute to these differences  include, but are not limited to,
      those discussed below.

      We  have  not had any  significant  revenues  since  inception.  Our  sole
      objective is to become an operating business.

      Our ability to become and continue as a going  concern is  dependent  upon
      obtaining  additional  substantial  capital.  Because we have virtually no
      funds and no  commitments  which would enable us to obtain  funds,  we may
      exhaust  our  limited  financial  resources  before  we are  ever  able to
      commence operations.









                                                                        Page 9.
<PAGE>


      ITEM 2. - MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
      RESULTS OF OPERATIONS (CONTINUED)

      RESULTS OF OPERATIONS

      We are currently in the  development  stage and have generated no revenues
      to date.  Our  activities  from  inception  to date  were  related  to our
      formation,  preparation  of our  business  model,  arranging  and planning
      financing  and the  acquiring  all rights,  title and interest in the A4+L
      compound.  During 2003 the  Company  completed  a reverse  acquisition  of
      Diamond  International  Group Inc.,  changed its name to Organetix,  Inc.,
      changed  its OTC-BB  symbol to OGTX and began a new  harvest of  materials
      necessary  to begin  formulating  new bulk  inventories  of the A4+L liver
      product in 2004. We have financed our  operations to date through the sale
      of our  securities  and  affiliates  of  our  shareholders  have  provided
      administrative services for which we have been billed.

      Operating costs for the period from inception to March 31, 2004 aggregated
      $562,545.  This includes  costs  incurred in research and  development  of
      $155,801,  operating expenses for our research facility in Peru of $60,260
      and fees paid to  various  professionals  for  research  as well as to our
      attorneys  and  accountants  in the  collective  amount of $177,736.  As a
      result of the above we realized a cumulative  loss of $562,545 or $.01 per
      share.

      Operating costs for the three-month period ended March 31, 2004 aggregated
      $167,863.  This includes  costs  incurred in research and  development  of
      $36,575,  operating  expenses for our research facility in Peru of $17,000
      and fees paid to  various  professionals  for  research  as well as to our
      attorneys and accountants in the collective amount of $52,765. As a result
      of the above we realized a loss of  $167,863  for the  three-month  period
      ended March 31, 2004 or $.00 per share.

      The Company is planning to purchase D & O insurance in the second  quarter
      of 2004 at which time the Company will  announce its new  management  team
      and additional members of the Board of Directors.

      LIQUIDITY AND CAPITAL RESOURCES

      From  inception  through March 31, 2004,  net cash used to fund  operating
      activities  totaled  $459,090,  net cash utilized by investing  activities
      totaled  $150,000 and net cash  provided by financing  activities  totaled
      $750,257.  For the three-month  period ended March 31, 2004, net cash used
      to fund  operating  activities  totaled  $269,565 and net cash provided by
      financing activities totaled $224,497.

      The Company has not generated  revenues and has financed its operations to
      date through the sale of  securities  and has received  $450,257 from such
      sales from inception to March 31, 2004. To date, the Company has also paid
      $150,000 towards its license for the A4+L compound.  As a result,  cash on
      hand was $141,167 as of March 31, 2004.

      The  Company is  presently  seeking  to raise  between $2 to $5 million in
      order  to  fund  research,  phytochemistry,   clinical  studies,  patents,
      manufacturing,  marketing  and to fund the Company's  exclusive  option to
      purchase the  intellectual  property for the A4+L liver  product. The
      Company has initiated a new 10 patient study to ascertain the
      effectiveness of its A4+L Liver Product relating to the quality of life of
      Hepatitis C patients.

      Specific criteria has been established by the medical team to
      scientifically measure the quality of life results of our product on
      Hepatitis C patients. We are planning on commencing our study during May
      2004 and are expecting results in early July 2004. Current discussions
      are ongoing with a number of potential  funding sources and we hope to
      have a  definitive  funding  agreement in place within the next 60 days.

      CRITICAL ACCOUNTING POLICIES AND ESTIMATES

                                                                        Page 10.
<PAGE>


      The  Company's  discussion  and analysis of its  financial  condition  and
      results of operations are based upon the its financial  statements,  which
      have been  prepared in accordance  with  accounting  principles  generally
      accepted  in  the  United  States.  The  preparation  of  these  financial
      statements  requires  the Company to make  estimates  and  judgments  that
      affect the reported amounts of assets, liabilities, revenues and expenses,
      and  related  disclosure  of  contingent  assets  and  liabilities.  On an
      on-going  basis,  the Company  evaluates its  estimates,  including  those
      related to bad debts,  income taxes and contingencies and litigation.  The
      Company bases its estimates on historical  experience and on various other
      assumptions  that are believed to be reasonable  under the  circumstances,
      the results of which form the basis for making  judgments  about  carrying
      values of assets and liabilities  that are not readily apparent from other
      sources.  Actual results may differ from these  estimates  under different
      assumptions or conditions.

      ITEM 3 - CONTROLS AND PROCEDURES

      EVALUATION OF DISCLOSURE  CONTROLS AND  PROCEDURES.  As of March 31, 2004,
      the Company's management carried out an evaluation,  under the supervision
      of the Company's Chief Executive  Officer and the Chief Financial  Officer
      of the  effectiveness  of the design and operation of the Company's system
      of  disclosure  controls and  procedures  pursuant to the  Securities  and
      Exchange Act , Rule 13a-15(e) and 15d-15(e) under the Exchange Act). Based
      upon that  evaluation,  the Chief  Executive  Officer and Chief  Financial
      Officer  concluded that the Company's  disclosure  controls and procedures
      were effective,  as of the date of their  evaluation,  for the purposes of
      recording,   processing,   summarizing  and  timely   reporting   material
      information required to be disclosed in reports filed by the Company under
      the Securities Exchange Act of 1934.

      CHANGES IN INTERNAL  CONTROLS.  There were no changes in internal controls
      over financial  reporting,  known to the Chief Executive  Officer or Chief
      Financial  Officer that occurred  during the period covered by this report
      that has  materially  affected,  or is likely to  materially  effect,  the
      Company's internal control over financial reporting.

                                                                        Page 11.
<PAGE>



                                     PART II

ITEM 1. LEGAL PROCEEDINGS
None.

ITEM 2. CHANGES IN SECURITIES
None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None

ITEM 5. OTHER INFORMATION
None

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

a. Exhibit Index

Exhibit 31.1 Certification of President and Principal Financial Officer

Exhibit  32.2  Certification  of Chief  Financial  Officer  and Chief  Executive
Officer

b. Reports on Form 8-K

On January 22, 2004, the Company filed an amended 8-K with respect to its change
of control.

                                   SIGNATURES

In accordance with the  requirements of the Exchange Act, the registrant  caused
this  report to be  signed on its  behalf  by the  undersigned,  thereunto  duly
authorized.

ORGANETIX, INC.


/s/ L. B. Brad Clarke
---------------------
Name: L. B. (Brad) Clarke
Title: President, Chief Financial Officer and Chairman of the Board
Date:  May 13, 2004

                                                                        Page 13.